Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

2
TO OUR SHAREHOLDERS
In fiscal 2000, which ended March 31, 2001, Eisai achieved record
consolidated results, due to the continued sales growth in global
markets of the Alzheimer’s disease treatment Aricept, and the proton
pump inhibitor Aciphex/Pariet. This achievement reflects the ongoing
support of shareholders and other stakeholders in the Company. On
behalf of everyone at Eisai, we would like to express our sincerest
appreciation.
Eisai sees our ultimate goal as satisfying customers—the patients
using our products—and our fundamental mission as determining
effective ways and allocating management resources effectively to
achieve this goal. Accordingly, we focus on developing pharmaceuticals
that satisfy unmet medical needs and enhance the quality of life
of patients worldwide. We also observe the highest standards of
quality and aim to provide information in easily accessible formats.
With Aricept, we have established a safe and effective course of
treatment for Alzheimer’s disease. Aricept has received approval in
78 countries and is playing a crucial role in efforts to treat patients
with mild to moderate Alzheimer's disease. We are also developing an
agent for treating sepsis, E5564, which is produced using proprietary
synthesis technologies. In the area of cancer research, we are pursuing
the development of substances with various mechanisms—such as
E7070 that affects the cell cycle at the G1 stage, tubulin antagonists
and antiangiogenics, which inhibit blood vessel formation—that offer
new hope for treating this disease. In the field of neurology, which we
have positioned as our most important strategic therapeutic area, we
are working toward the development of effective treatments for
neurogenerative disorders including multiple sclerosis and other
illnesses. Substances currently in development include the serotonin
receptor antagonist E2101, and the amino-3-hydroxy-5-methyl-4isoxazolepropionate
(AMPA) type glutamate receptor antagonist
E2007, for which we have received a concept patent for the inhibition
of neural dysfunction associated with multiple selerosis. Our research
in the neurology area also includes the development of additional
indications for Aricept.
Eisai Annual Report 2001